This is an open label randomized controlled clinical trial designed to compare the effects of empagliflozin and dapagliflozin in adults with prediabetes These medicines are SGLT2 inhibitors that lower blood sugar by increasing glucose loss through urine and may also improve insulin sensitivity and body weight

Adults with prediabetes who have not used similar medicines earlier will be enrolled Participants will be randomly assigned into three groups one group will receive empagliflozin plus standard care one group will receive dapagliflozin plus standard care and one group will receive standard care alone control for a fixed study period The main aim is to evaluate which approach is more effective in improving glycaemic control and preventing progression to diabetes

The primary outcome is change in HbA1c from baseline to 6 months HbA1c will be measured at baseline 3 months and 6 months Secondary assessments include changes in body weight lipid profile blood pressure and insulin resistance HOMA IR Safety will be monitored throughout the study by regular follow up visits to record any adverse events

Data will be analysed statistically to identify which group shows better metabolic improvement with fewer adverse effects The findings may help guide early management of prediabetes and delay the onset of diabetes using safe and effective therapy